A practical review of efficacy, safety, and real world considerations for advanced practice providers
This is a must-read JDD article on JAK inhibitors for alopecia areata. The review summarizes current evidence and clinical experience with Janus kinase inhibitors in alopecia areata, focusing on the three FDA approved agents baricitinib, ritlecitinib, and deuruxolitinib. It reviews clinical features and diagnostic pearls for alopecia areata, outlines expected treatment outcomes, and discusses safety signals and monitoring considerations drawn from trials and real world use.
The piece is written for clinicians who manage patients with hair loss and addresses practical topics such as setting patient expectations, assessing response, and navigating adverse event counseling and follow up. The authors synthesize efficacy and tolerability data without extensive mechanistic detail, making the review useful for busy dermatology HCPs and advanced practice providers seeking a clinically focused update.
Read the full JDD review for detailed summaries of trial and postmarketing experience, guidance on patient selection and monitoring, and suggested talking points for counseling patients starting JAK inhibitor therapy.
J Drugs Dermatol. 2026;25(3):204-210. doi:10.36849/JDD.9292
Blog write-up assisted by AI
